Nacuity Enters Licensing Agreement and Strategic Partnership with Arctic for HCCAA Therapy

Nacuity Pharmaceuticals said it entered into a licensing agreement and strategic partnership with Arctic Therapeutics International for the development and commercialization of NPI-001 in Iceland for a rare neurological condition primarily seen in Iceland.

Photo: Halden Conner, chairman, CEO and co-founder of Nacuity Pharmaceuticals

Hereditary cystatin C amyloid angiopathy (HCCAA) is an inherited, rare amyloid disease primarily seen in the Icelandic population that leads to paralysis, dementia, and death in young adults.

NPI-001 is Nacuity’s proprietary, GMP-grade formulation of N-acetylcysteine amide (NACA) being developed for the treatment of a broad range of diseases associated with oxidative stress, including HCCAA, which is caused by a leucine to glutamine variant of human cystatin C (hCC). Clinical and in vitro data utilizing N-acetylcysteine and NACA for the treatment of HCCAA support a strong mechanistic rationale for NPI-001 as a potential effective therapy for the treatment of HCCAA.

NPI-001 has been granted orphan designation by the U.S. Food and Drug Administration for the treatment of retinitis pigmentosa in Usher syndrome and is currently being evaluated in a phase 1/2 clinical trial for Usher syndrome.

“This strategic collaboration will help progress our mission to develop therapies that stop oxidative tissue damage and expand our NPI-001 platform to provide a treatment option for a critically underserved disease,” said Halden Conner, chairman, CEO and co-founder of Nacuity Pharmaceuticals.

Under the terms of the agreement, Nacuity will provide exclusive rights to Arctic to develop and commercialize NPI-001 for HCCAA in Iceland and related CAAs worldwide. Nacuity and Arctic will collaborate on all regulatory approval and development activities related to NPI-001 for the treatment of HCCAA. Other terms of the agreement were not disclosed.

Author: Rare Daily Staff